Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

Central Nervous System Lymphoma Clinical Trial

Official title:

Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00967200
• Other study ID #: 7745
• Status: Completed
• Phase: N/A
• First received: August 26, 2009
• Last updated: November 23, 2015
• Start date: November 2003
• Est. completion date: November 2015

Study information

• Verified date: November 2015
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Commission nationale de l'informatique et des libertés
• Study type: Observational

Clinical Trial Summary

RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.

Description:

OBJECTIVES:

Primary

• To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.

Secondary

• To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.

OUTLINE: This is a multicenter study.

Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: November 2015
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing

Exclusion :

No concurrent participation in other trials that require a period of exclusion

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Central Nervous System Lymphoma

Intervention

Other:
• laboratory biomarker analysis
laboratory biomarker analysis
• pharmacogenomic studies
pharmacogenomic studies

Locations

Country	Name	City	State
France	CHU Montpellier	Montpellier
France	Clinique Gui de Chauliac	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathophysiology of gliomas	Pathophysiology of gliomas that may predict prognosis and progression or that could identify new therapeutic	1 day	No
Secondary	Identification of molecular	Identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic	1 day	No